Biogen Inc.
Biogen Reports Strong 2025 Financial Results and Provides 2026 Guidance
Summary
On February 6, 2026, Biogen Inc. announced its fourth quarter and full year 2025 financial results. Total revenue for 2025 was $9.9 billion, with Non-GAAP diluted EPS at $15.28, exceeding the upper end of the guidance range. Biogen also provided financial guidance for 2026, expecting Non-GAAP diluted EPS between $15.25 and $16.25, despite anticipating a mid-single digit percentage decline in total revenue compared to 2025. Key growth products saw increased demand, contributing to overall revenue growth.
Profitelligence Alerts
Get alerts for BIIB
Be first to know when Biogen Inc. files with the SEC.
Filing Categories
Advertisement
About Biogen Inc.
Biogen Inc. is a globally recognized biotechnology company committed to discovering, developing, and delivering innovative therapies for neurological diseases. With a focus on serious medical conditions, Biogen creates therapies aimed at treating conditions like multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. The company invests heavily in research and development to pioneer treatments that improve patients' quality of life and addresses critical unmet medical needs. Biogen's influence spans various therapeutic areas in the healthcare sector, making notable strides in both neurodegenerative and rare diseases. The company's portfolio includes a range of biologics, gene therapy, and small molecule drugs, highlighting its strategic diversity. As a prominent player within the biopharmaceutical industry, Biogen collaborates with academic institutions, research organizations, and other biotech firms to enhance its research pipeline and bring new solutions to market. Biogen's role in the financial markets is underscored by its contributions to healthcare innovation and its impact on global health outcomes. Headquartered in Cambridge, Massachusetts, Biogen continues to leverage its scientific expertise and industry alliances to remain at the forefront of biotechnology, influencing both investors and the broader medical community.
Official SEC Documents
Advertisement